Equities

WAVE Life Sciences Ltd

WAVE Life Sciences Ltd

Actions
  • Price (USD)6.03
  • Today's Change-0.010 / -0.16%
  • Shares traded177.45k
  • 1 Year change+50.38%
  • Beta-1.1351
Data delayed at least 15 minutes, as of Mar 28 2024 17:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

  • Revenue in USD (TTM)113.31m
  • Net income in USD-57.51m
  • Incorporated2012
  • Employees266.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Korro Bio Inc0.00-59.32m709.25m48.00--1.78-----83.09-83.090.0049.740.00----0.00-65.05-29.26-77.66-34.01-------288.37----0.00---100.00--3.67------
Nurix Therapeutics Inc76.99m-143.95m710.92m284.00--3.53--9.23-2.65-2.651.424.120.1994----271,081.00-37.27-33.01-46.83-39.66-----186.98-260.65----0.00--99.3115.5020.19--39.42--
Northwest Biotherapeutics Inc1.93m-64.37m713.98m25.00------369.56-0.0573-0.05730.0017-0.040.0653----77,280.00-211.53-381.58---------3,240.11-6,479.25--------14.8036.2138.71--77.88--
Y-mAbs Therapeutics Inc84.82m-21.43m722.32m100.00--7.14--8.52-0.4909-0.49091.942.310.62991.934.85848,190.00-15.91-44.23-19.40-50.4586.60---25.26-181.135.27--0.00--29.96--77.58------
Aurinia Pharmaceuticals Inc175.51m-78.02m723.09m300.00--1.90--4.12-0.5454-0.54541.232.630.34450.4399.34585,043.30-15.31-25.97-17.42-28.2491.94---44.45-137.644.99--0.1925--30.95227.9027.88--57.11--
Applied Therapeutics Inc9.99m-119.76m725.32m25.00------72.58-1.42-1.420.1288-0.2020.2145----399,720.00-257.01-140.37---240.93-----1,198.47-4,476.42-------------45.15------
Zymeworks Inc76.01m-118.67m726.85m272.00--1.57--9.56-1.74-1.741.106.570.1236--2.88279,455.90-19.30-22.58-22.01-26.90-----156.13-91.17----0.0003---81.577.47-195.44--3.58--
Exscientia PLC (ADR)30.92m-181.88m728.97m481.00--1.45--23.58-1.46-1.460.24843.980.04--2.4064,272.87-23.54---26.71---26.74---588.31------0.0445---0.4971---141.17------
Wave Life Sciences Ltd113.31m-57.51m738.60m266.00--18.16--6.52-0.5397-0.53971.070.39870.5378----425,958.70-27.30-56.98-70.41-102.38-----50.76-353.20----0.00--3,005.1051.0464.46---35.44--
OPKO Health Inc863.49m-188.86m745.78m3.93k--0.5956--0.8637-0.2513-0.25131.151.800.41337.806.89219,718.60-9.03-7.14-10.03-8.1436.8434.42-21.86-13.831.22-15.240.1574---14.01-2.7042.49---10.19--
Astria Therapeutics Inc0.00-72.89m746.68m59.00--3.78-----2.34-2.340.005.920.00----0.00-30.04-64.48-31.37-68.34------------0.00-------40.62------
enGene Holdings Inc0.00-106.80m751.34m33.00--6.41-----4.60-4.600.002.69------0.00-------------------1.370.2653-------260.87------
Allogene Therapeutics Inc95.00k-327.27m754.15m232.00--1.47--7,938.42-2.09-2.090.00063.040.0001----409.48-44.70-28.46-47.65-30.21-----344,489.50-1,123.44----0.00---39.10--3.86---14.06--
Longboard Pharmaceuticals Inc0.00-54.42m755.64m50.00--12.57-----2.39-2.390.001.670.00----0.00-89.72---105.91--------------0.00-------23.84------
Cullinan Oncology Inc0.00-153.16m763.55m85.00--1.68-----3.70-3.700.0010.580.00----0.00-29.68-12.37-31.19-12.93-------1,026.78----0.00-------237.72---4.44--
Data as of Mar 28 2024. Currency figures normalised to WAVE Life Sciences Ltd's reporting currency: US Dollar USD

Institutional shareholders

55.38%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 31 Dec 202318.20m15.29%
Maverick Capital Ltd.as of 31 Dec 20238.45m7.10%
M28 Capital Management LPas of 31 Dec 20237.37m6.20%
Adage Capital Management LPas of 31 Dec 20235.99m5.03%
683 Capital Management LLCas of 31 Dec 20235.60m4.71%
BlackRock Fund Advisorsas of 31 Dec 20234.90m4.12%
Bellevue Asset Management AGas of 31 Dec 20234.49m3.78%
Kynam Capital Management LPas of 31 Dec 20233.93m3.30%
PRIMECAP Management Co.as of 31 Dec 20233.76m3.16%
Point72 Asset Management LPas of 31 Dec 20233.21m2.70%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.